Another Study of Pioglitazone Use and Risk for Bladder Cancer

Evidence is mixed on whether pioglitazone (Actos), an oral thiazolidinedione drug used for managing type 2 diabetes, is associated with excess risk for bladder cancer. In this retrospective cohort study from four European countries, researchers assessed risk for bladder cancer in 56,000 patients (age, >40) with type 2 diabetes who started treatment with pioglitazone. Participants were matched (based …